Coloplast ASCLPBF 72 Receivables Turnover is 1.55 as of Mar. 2026. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $126.21 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Coloplast AS ranks better than 56.23% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Coloplast AS's Revenue for the
three
months ended in Mar. 2026 was $1,096 Mil. Coloplast AS's average Accounts Receivable for the
three
months ended in Mar. 2026 was $707 Mil.
Hence, Coloplast AS's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.55.
Coloplast AS (OTCPK:CLPBF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Coloplast AS Receivables Turnover Related Terms
Coloplast AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBF vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a Receivables Turnover of 1.55 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Coloplast AS and its competitors. According to the industry distribution chart, Coloplast AS ranks #355 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 43.8%.
Is Coloplast AS's Receivables Turnover too high?
Coloplast AS's current Receivables Turnover is 1.55. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Coloplast AS's value of 1.55 is 71.9% below this industry median. Based on the distribution chart, Coloplast AS ranks #355 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #355 out of 811 companies for Receivables Turnover. This puts Coloplast AS in the upper half of its industry. The industry median Receivables Turnover is 5.51. Coloplast AS's value of 1.55 is 71.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Receivables Turnover of 1.55 is 71.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Receivables Turnover is 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.21, compared to a current price of $60.29 — trading 52.2% below its estimated fair value. The current Receivables Turnover is 1.55 and 71.9% below the Medical Devices & Instruments industry median of 5.51. Coloplast AS's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Receivables Turnover is 1.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $60.29 is trading 52.2% below its estimated GF Value™ of $126.21.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
Receivables Turnover: 1.55
GF Value™: $126.21 vs. price of $60.29 (52.2% below fair value)
Industry Position: 71.9% below the Medical Devices & Instruments median (#355 of 811)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
